GRAIL, Inc. (NASDAQ:GRAL) Receives Average Rating of “Hold” from Brokerages

GRAIL, Inc. (NASDAQ:GRAL) has earned an average rating of “Hold” from the six analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $107.8333.

Several brokerages have recently weighed in on GRAL. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Guggenheim upped their price target on shares of GRAIL from $100.00 to $130.00 and gave the company a “buy” rating in a report on Monday, January 26th. Canaccord Genuity Group lifted their price objective on shares of GRAIL from $85.00 to $105.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Morgan Stanley boosted their target price on shares of GRAIL from $85.00 to $110.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. Finally, TD Cowen started coverage on shares of GRAIL in a report on Thursday. They set a “hold” rating and a $114.00 target price for the company.

Institutional Investors Weigh In On GRAIL

Several hedge funds have recently modified their holdings of the stock. Caxton Associates LLP acquired a new stake in GRAIL in the second quarter valued at approximately $3,320,000. NWF Advisory Services Inc. bought a new position in shares of GRAIL during the 2nd quarter valued at $1,062,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of GRAIL in the 3rd quarter valued at $885,000. Legal Advantage Investments Inc. acquired a new stake in shares of GRAIL in the 3rd quarter valued at $1,242,000. Finally, Sheets Smith Investment Management bought a new stake in GRAIL in the third quarter worth $1,689,000.

GRAIL Price Performance

GRAL opened at $102.28 on Thursday. The business has a 50 day moving average price of $97.29 and a two-hundred day moving average price of $75.64. The company has a market capitalization of $3.99 billion, a price-to-earnings ratio of -8.79 and a beta of 4.52. GRAIL has a 1-year low of $20.44 and a 1-year high of $118.84.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.